Equities research analysts at Maxim Group lowered their target price on shares of Intellipharmaceutics Intl Inc (USA) (NASDAQ:IPCI) from $9.00 to $7.00 in a research note issued to investors on Thursday, StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective suggests a potential upside of 72.84% from the company’s current price. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) weekly performance is -7.41%. On last trading day company shares ended up $3.75. Analysts mean target price for the company is $8.88. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) distance from 50-day simple moving average (SMA50) is -9.10%.
Flamel Technologies S.A. (ADR) (NASDAQ:FLML) will release financial results for the first quarter of fiscal year 2014 on Monday, May 12, 2014, before the market open. A conference call to discuss these results has been scheduled for Monday, May 12th at 10:00 a.m. ET. A question and answer period will follow management’s prepared remarks. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) shares advanced 2.16% in last trading session and ended the day on $11.36. Gross Margin is 76.70% and its return on assets is -32.80%. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) quarterly performance is 17.11%.
Delcath Systems, Inc. (NASDAQ:DCTH) reported financial results and corporate developments for the fiscal first quarter ended March 31, 2014. Delcath Systems, Inc. (NASDAQ:DCTH) shares moved down -3.80% in last trading session and was closed at $3.04, while trading in range of $3.03 – $3.23. Delcath Systems, Inc. (NASDAQ:DCTH) year to date (YTD) performance is -26.92%.
Columbia Laboratories Inc (NASDAQ:CBRX) CEO Frank Condella, Jr. purchased 10,000 shares of the stock in a transaction dated Monday, May 5th. The shares were purchased at an average price of $6.65 per share, for a total transaction of $66,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 45,345 shares in the company, valued at approximately $301,544. Columbia Laboratories Inc. (NASDAQ:CBRX) ended the last trading day at $6.58. Company weekly volatility is calculated as 3.37% and price to cash ratio as 5.80. Columbia Laboratories Inc. (NASDAQ:CBRX) showed a negative weekly performance of -0.75%.